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Abstract
Background:  We recently have shown that Charged multivesicular protein/Chromatin modifying
protein1A (Chmp1A) functions as a tumor suppressor in human pancreatic tumor cells. Pancreatic cancer
has the worst prognosis of all cancers with a dismal 5-year survival rate. Preclinical studies using ATRA for
treating human pancreatic cancer suggest this compound might be useful for treatment of pancreatic
cancer patients. However, the molecular mechanism by which ATRA inhibits growth of pancreatic cancer
cells is not clear. The objective of our study was to investigate whether Chmp1A is involved in ATRA-
mediated growth inhibition of human pancreatic tumor cells.
Results: We performed microarray studies using HEK 293T cells and discovered that Chmp1A positively
regulated Cellular retinol-binding protein 1 (CRBP-1). CRBP-1 is a key regulator of All-trans retinoic acid
(ATRA) through ATRA metabolism and nuclear localization. Since our microarray data indicates a
potential involvement of Chmp1A in ATRA signaling, we tested this hypothesis by treating pancreatic
tumor cells with ATRA in vitro. In the ATRA-responsive cell lines, ATRA significantly increased the protein
expression of Chmp1A, CRBP-1, P53 and phospho-P53 at serine 15 and 37 position. We found that
knockdown of Chmp1A via shRNA abolished the ATRA-mediated growth inhibition of PanC-1 cells. Also,
Chmp1A silencing diminished the increase of Chmp1A, P53 and phospho-P53 protein expression induced
by ATRA. In the ATRA non-responsive cells, ATRA did not have any effect on the protein level of Chmp1A
and P53. Chmp1A over-expression, however, induced growth inhibition of ATRA non-responsive cells,
which was accompanied by an increase of Chmp1A, P53 and phospho-P53. Interestingly, in ATRA
responsive cells Chmp1A is localized to the nucleus, which became robust upon ATRA treatment. In the
ATRA-non-responsive cells, Chmp1A was mainly translocated to the plasma membrane upon ATRA
treatment.
Conclusion: Collectively our data provides evidence that Chmp1A mediates the growth inhibitory
activity of ATRA in human pancreatic cancer cells via regulation of CRBP-1. Our results also suggest that
nuclear localization of Chmp1A is important in mediating ATRA signaling.
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Background
Retinoids are natural or synthetic derivatives of vitamin A.
Nuclear receptors and cellular binding proteins are
involved in mediating the biological effects of retinoids
[1-4]. The active form of retinoids (ATRA or 9-cis-RA)
interacts with their nuclear receptors, retinoic acid recep-
tors (RAR α, β, and γ), and retinoic × receptors (RXR α, β,
and γ). All-trans retinoic acid (ATRA) is one of the most
physiologically active members of the retinoid family. By
binding to its receptor RAR, ATRA exercises a broad spec-
trum of biological effects such as proliferation and differ-
entiation [5]. Because of anti-proliferative effects of ATRA,
it has been used as a therapeutic and/or preventive agent
in certain cancers such as promyelocytic leukemia [6].
There are two cellular retinol-binding proteins; CRBP-I
and II [7]. CRBP-1 is required for biosynthesis and metab-
olism of retinoic acid. Cellular retinol-binding protein I
(CRBP-I) controls ATRA activity by presenting the retinol
to various enzymes for retinoic acid synthesis [7-9]. CRBP-
I protein expression was previously shown to correlate
with tumor growth [8,10]. P53, a known tumor suppres-
sor, is mutated in most tumors including pancreatic can-
cer. The mutation of P53 causes further mutation of the
P53 gene itself, an increase in an ubiquitin-dependant
degradation of P53 mediated by MDM2 [11], and an inac-
tivation of P53 [12]. P53, located at chromosome 17, has
a DNA binding domain and acts as a "genome gate-
keeper" [13]. The inherited loss of one copy of an allele of
P53 [14-16] usually results in several independent tumors
in early adulthood (Li-Faumeni syndrome) [17].
Chmp1A (Charged multivesicular protein 1A/Chromatin
modifying protein 1A) belongs to the class E family of Vps
and is also called Vps 46p [18,19]. Chmp1A was shown to
physically associate with the multivesicular sorting pro-
tein, SKD1/VPS4 (Vacuolar protein-sorting 4), with
AMSH, an endosome-associated ubiquitin isopeptidase,
and with VPS4 ATPases [18]. Chmp1A localizes at the
endosomes, where it functions in the formation and sort-
ing of multivesicular bodies (MVBs) [18]. Chmp1A was
also reported to silence gene activation by interacting with
a transcriptional repressor Polycomb-group (PcG) pro-
tein, BMI1 [19-21]. We have recently shown that Chmp1A
is a novel tumor suppressor, especially in the pancreas.
Chmp1A mRNA and protein was reduced and/or altered
(protein) in various human pancreatic tumors. Stable
over-expression of Chmp1A in PanC-1 cells resulted in
cell growth inhibition and tumor xenograft inhibition,
respectively. In contrast, silencing of Chmp1A in PanC-1
cells resulted in the elevation of cell and xenograft tumor
growth. Over-expression of Chmp1A strongly increased
the protein level of P53 and phospho-P53 indicating that
Chmp1A regulates tumor growth potentially through a
P53 signaling pathway [22].
Pancreatic cancer has the worst prognosis of all cancers
with a dismal 5-year survival rate [23,24]. ATRA alone or
in combination with other chemotherapeutic reagents has
been successful in treating tumors [25-27]. Preclinical
studies using ATRA for treating human pancreatic cancer
suggest this compound might be useful for treatment of
patients in pancreatic cancer. However, the molecular
mechanism by which ATRA inhibits growth of pancreatic
cancer cells is not clear. This paper focuses on the role of
Chmp1A in ATRA mediated growth inhibition. The objec-
tive of our study was to investigate whether Chmp1A
expression and/or localization is essential for ATRA medi-
ated growth inhibition of human pancreatic tumor cells.
Materials and methods
Antibodies and chemicals
Rabbit polyclonal antibody against Chmp1A was gener-
ated in our laboratory by using recombinant Chmp1A
protein (Belogortseva and Park, unpublished) and suc-
cessfully used for the previous studies [22]. Other anti-
bodies were purchased from commercial sources: rabbit
polyclonal antibodies against P53 (Cell Signaling) and
Phospho-P53 (Cell Signaling); rabbit polyclonal antibod-
ies against phospho-specific P53 at Ser37 (Cell Signaling),
and mouse monoclonal antibody phospho-specific P53 at
Ser15 (Cell Signaling); mouse monoclonal antibodies
against Gapdh (Cell Signaling), and rabbit polyclonal
antibody against CRBP-1 (Abcam). Goat anti-rabbit/
mouse HRP conjugated secondary antibody was pur-
chased from Chemicon. All Trans Retinoic Acid was pur-
chased from Fluka. Puromycin was purchased from
Invitrogen. All other chemical reagents were purchased
from Sigma, unless otherwise described.
Cell Culture
All cell lines were obtained from American Type Culture
Collection (Manassas, VA). PanC-1 (human pancreatic
ductal tumor cells, poorly differentiated), CRL-2151
(mouse acinar tumor cells), and HEK 293T (human
embryonic kidney, CRL-11268) cells were cultured in
Dulbecco's modified Eagle's medium containing 10%
fetal bovine serum (FBS, Gibco). Capan-2 (human pan-
creatic ductal tumor, well differentiated) cells were cul-
tured in McCoy with 10% fetal bovine serum. All cell
culture assays were performed at 37°C under 5% CO2.
RT-PCR (reverse transcriptase-PCR)
HEK 293Tcells (CRL-11268) were transiently transfected
with empty CS2+ (control) or Chimp1A-CS2+ plasmid
using Plus and Lipofectamine reagent (Invitrogen). Total
RNA was isolated 18 hours post-transfection using Trizol
reagent (Invitrogen). Quality and quantity of isolated
RNA was analyzed using Bioanalyzer (Agilent). RT-PCR
(reverse-transcriptase-PCR) was performed using Titan
one tube RT-PCR system that was purchased from Roche.Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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For each reaction, 500 ng of total RNA was reverse tran-
scribed and used to amplify Chmp1A and CRBP-1. PCR
products were separated on 1.5% agarose gel containing
Ethidium bromide. The forward and backward primers
used to detect Chmp1A was: 5'-GAGACAGCGGGTCCG-
TAAC-3', and 5'-ACCTGGGCCATATTCTTGGT-3'. CRBP-1
primer used in this experiment was described in Arap-
shian, A., et al., [28]. The cycling parameter for amplifying
PCR products was: 94° for 2 min, 10 cycles of (94° for 30
second, 48° for 30 second, 68° for 1 min), followed by
15, or 18 additional cycles of (94° for 30 second, 48° for
30 second, 68° for 1 min (+5 second per cycle), and last
step is 68° for 7 min.
ATRA treatment
PanC-1 and Capan-2 cells were seeded at 350,000 and
300,000 cells per 10 cm plate respectively. CRL-2151 cells
were seeded at higher density since these cells are much
smaller than Capan-2 or PanC-1 cells. The next day, cells
were replaced with fresh media containing either vehicle
(DMSO) or ATRA (20 μM final concentration). ATRA
treated cells were kept in the dark since ATRA is light sen-
sitive. Every other day, cells were replaced with fresh
media containing either DMSO or ATRA. The cells were
cultured for up to 6 days for the following experiments.
For growth assays we maintained and treated cells in
either regular or charcoal stripped FBS supplemented
media. Charcoal stripped FBS was purchased from Invit-
rogen. We have received similar results with either regular
or charcoal stripped serum. The data presented here was
from the results we obtained with media supplemented
with charcoal stripped serum.
Generation of stable Chmp1A knockdown clones of PanC-
1 cells
PanC-1 cells were cultured in DMEM media supplied with
10% FBS. RNAintro™ pSM2 retroviral vector (Open Bio-
systems) was used to sub-clone non-silencing or Chmp1A
shRNAs. The Chmp1A shRNA sequence was designed
using online software from Open Biosystems. This vector
contains a puromycin-resistant marker site for positive
colony selection. The specificity of Chmp1A shRNA was
verified by transient transfection using Arrest-In transfect
reagent (Open Biosystem) followed by Western blotting.
To generate stable cell lines, shRNAs targeted to Chmp1A
or non-silencing control were transfected into PanC-1
cells. Stable transfectants were selected in the presence of
2 ug/ml puromycin (Invitrogen), whose working concen-
tration was determined by kill curve. Cells derived from
these transfectants were used for Western blotting to con-
firm the decrease of Chmp1A protein expression.
Chmp1A knockdown stable Panc-1 cells were maintained
in DMEM media supplied with 10% FBS containing 1ug/
ml puromycin.
Stable over-expression of Chmp1A in PanC-1 cells
Tet-On advanced inducible gene expression system was
used to generate conditional stable clones of PanC-1 cells
(Clontech). Transfection was performed with CalPhos™
Mammalian Transfection Kit (Clontech) according to the
manufacturer's instructions. Detailed protocol was
described in Li et al., [22].
Transient over-expression of Chmp1A in CRL-2151 cells
Equal numbers of CRL-2151 cells were seeded in 10 cm
dishes one day before transfection. Next day, 5 ug of con-
trol CS2+ or Chmp1A-CS2+ plasmid was transiently
transfected using Plus and Lipofectamine reagent follow-
ing the company's instruction (Invitrogen). Cell numbers
were counted the following three days, three dishes per
each day for control or Chmp1A over-expression, respec-
tively. After cell counting, cells were lysed for protein iso-
lation. Protein concentration was determined using BCA
reagent (Pierce) for Western blot analysis.
Western blot analysis
The cell lysates were prepared from cells using RIPA buffer
(Boston Bioproducts Inc) plus complete mini protease
inhibitor cocktail (Roche). Protein concentration of cell
lysates was determined using BCA assay kit (Pierce). Equal
amounts of cell lysates were subjected to 10% SDS-PAGE,
and the proteins were electroblotted to nitrocellulose
membranes. After blotting the membrane was incubated
overnight with appropriate primary antibody (1: 400 to 1:
1000 dilution) followed by peroxidase-conjugated sec-
ondary antibody (1 to 3 hours) and was developed using
an enhanced chemiluminescence kit (Amersham). To
examine the effect of ATRA on protein level, we determine
the density of each sample by correcting for Gapdh after
densitometric analyses. On each day, the density of pro-
teins changed by ATRA treatment was determined by set-
ting control DMSO as "1" (Figures 1, 2, 3 and 4).
Untreated cells show a similar expression level of proteins
as shown in Day 1 control and data was not included in
the figures.
Confocal microscopic analysis
PanC-1 and CRL-2151 cells were seeded onto sterile glass
coverslips in twelve-well plates at an approximate density
of 0.5 × 105 cells/well in DMEM (Gibco) containing 10%
FBS (Gibco), 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Gibco). These cells were incubated at 37°C with
5% CO2 (Gibco). The following day, cells were treated
with vehicle DMSO or ATRA dissolved in DMSO (20
umol, final concentration). Following 24, 48, and 72
hours after ATRA treatment, cells were washed with 1×
cold PBS, and fixed with 4% formaldehyde in 1 × PBS at
room temperature for 30 min. Fixed cells were washed
with PBS before being permeabilized in PBS/0.1% Triton
X-100 (Sigma) for 5–10 min at room temperature. Fol-Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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lowing permeabilization cells were washed three times in
cold PBS and incubated in blocking solution (PBS, 10%
heat inactivated FBS) for 30 min. Next, the cells were incu-
bated with Chmp1A antibody in 1 × PBS containing 5%
heat inactivated serum (blocking buffer) overnight at
4°C. After being washed three times with 1 × PBS cells
were incubated with anti-rabbit Alexa Fluor 488 second-
ary antibody (Molecular Probes). In each case secondary
antisera were used at a dilution of 1:500 in blocking
buffer. Cells were washed in 1 × PBS and mounted on the
slide using Vectashield (Vector Laboratories, Inc. Burlin-
game). Confocal images were taken by using a laser-scan-
ning microscope (Carl Zeiss LSM510) at Marshall
University Imaging Core.
Statistical Analysis
Statistical analysis was performed with Sigma Stat soft-
ware using paired student t-test  analysis. All numerical
data are reported as the Mean ± SEM. P values less than
0.05 were considered statistically significant, and all P val-
ues are one tail.
Results
Over-expression of Chmp1A positively regulates CRBP-I 
expression
We performed microarray studies in HEK 293T cells to
understand the functions and/or mechanisms of
Chmp1A. Cellular retinol binding protein-1 (CRBP-I) was
identified as one of the up-regulated genes when Chmp1A
was over-expressed in HEK 293T cells. Chmp1A [Gen-
Bank: NM_002768] and CRBP-1 [GenBank: NM_002899]
showed 9.44-fold and 3.46-fold increases respectively,
upon Chmp1A over-expression compared with control
(data not shown). Reverse transcriptase PCR (RT-PCR)
was carried out to verify microarray data. As shown in Fig-
ure 1A, CRBP-1 mRNA level was increased by 3.3 fold
compared to control at 31 cycles. Chmp1A mRNA expres-
sion was examined as positive control for RT-PCR which
was increased 1.9 fold by Chmp1A over-expression com-
pared to control (Figure 1A). Next, we investigated
whether Chmp1A regulates CRBP-1 in PanC-1 cells. Dox-
ycycline (dox) inducible Chmp1A stable clones were gen-
erated and tested for the induction of Chmp1A expression
as described in our previous paper [22]. As previously
shown Chmp1A expression was dramatically increased by
dox-dependent induction of Chmp1A in two independ-
ent stable clones of PanC-1 cells. CRBP-1 protein was also
increased in clone 1 and 2 by 1.4 and 1.6 folds respec-
tively (Figure 1B). The same stable clones without dox
supplement were used as controls. Since CRBP-1 is
involved in retinoid metabolism and function we devel-
oped a hypothesis that Chmp1A might be involved in
ATRA signaling.
Chmp1A over-expression positively regulates CRBP-1 Figure 1
Chmp1A over-expression positively regulates CRBP-1. (A) HEK 293T cells were transfected with either empty CS2+ 
or Chmp1A-CS2+ plasmid. 18 hours after transfection cells were processed for total RNA isolation. Reverse transcriptase 
PCR (RT-PCR) indicates that Chmp1A and CRBP-1 transcripts were increased 1.5 and 3.3 folds respectively at 31 cycles com-
pared to control. Gapdh was used as RT-PCR control. (B) Chmp1A expression was induced by the addition of doxycycline to 
the media in two independent stable clones of PanC-1 cells. Cells were lysed two days after the doxycycline supplement and 
processed for Western blot analysis. Chmp1A and CRBP-1 protein was increased upon Chmp1A over-expression. Con: Con-
trolMolecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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ATRA induced growth inhibition and an increase of 
Chmp1A, CRBP-1, P53 and phospho-P53 protein in human 
pancreatic ductal tumor cells
Human pancreatic ductal tumor cells, Capan-2 (well dif-
ferentiated) and PanC-1 (poorly differentiated), were
treated with ATRA, 20 μM final concentrations. There are
two reasons we chose to use 20 μM of ATRA for the fol-
lowing experiments. First, we observed clear growth inhi-
bition at 20 μM of ATRA in our experiments with various
doses of ATRA (1 μM, 5 μM, 10 μM, 15 μM, and 20 μM
(data not shown). Pancreatic tumor cell lines were treated
with 20 μM or higher concentrations of ATRA in previ-
ously published reports [29,30]. Second, we need to use a
sufficient amount of ATRA to determine the effect of
Chmp1A knockdown on ATRA-mediated growth inhibi-
tion. For growth assays, cell number was counted on a
daily basis for 5 days after ATRA treatment using a hemo-
cytometer. ATRA treatment induced growth inhibition of
Capan-2 and PanC-1 cells (Figures 2A and 3A, respec-
tively) compared with vehicle DMSO treatment. Based on
P-value of less than 0.05, two groups showed significant
difference in growth, which is consistent with the results
reported from other researchers [30-33]. To determine if
Chmp1A is involved in the growth inhibition of ATRA, we
performed Western blot analysis. As shown in Figures 2B
and 3B, the level of Chmp1A protein was increased upon
ATRA treatment in both cell lines compared to control.
The increase in Chmp1A protein with ATRA treatment in
Capan-2 cells was significant but appeared to be transient,
observed only on day 2. However, PanC-1 cells showed an
increase in Chmp1A upon ATRA treatment in all the days
tested. Although it showed the highest ratio of increase in
Chmp1A protein on day 1, it exhibited robust expression
of Chmp1A on day 3 and 4 in both control and ATRA
treated cells (Figure 3B). CRBP-1 showed similar changes
in protein expression to that of Chmp1A. In Capan-2
cells, the difference in CRBP-1 expression was transient,
limited to day 1 and 2 (1.36 and 1.94 fold increase each)
upon ATRA treatment (Figure 2B). Capan-2 cells have a
longer doubling time (about 90 hours [34]) than PanC-1
cells (about 50 hours [35]) and did not show significant
growth inhibition (P > 0.05) or increase in Chmp1A
expression, one day after ATRA treatment (Figure 2A). The
changes in CRBP-1 in PanC-1 cells upon Chmp1A over-
expression was not robust, maximum 1.3 fold increase
compared to control (Figure 3B).
The growth inhibition of Capan-2 cells by ATRA was accompanied by an increase in the protein level of Chmp1A, CRBP-1,  P53, and phospho-P53 Figure 2
The growth inhibition of Capan-2 cells by ATRA was accompanied by an increase in the protein level of 
Chmp1A, CRBP-1, P53, and phospho-P53. (A) Capan-2 cells were counted and equal numbers of cells were seeded in 10 
cm tissue culture dishes. Next day, cells were treated with control DMSO or ATRA. The following 5 Days, cells were counted 
and plotted for the graph. Dashed line with square represents DMSO treated and straight line with circle represents ATRA 
treated. On Day 1 the cells did not show any difference in growth. However, the growth was inhibited significantly (based on 
P-value) by ATRA treatment from Day 2 on. (B, C) The cells were processed for Western blot analysis following lysis. Notice 
the increase of protein level of Chmp1A, CRBP-1, P53 and phospho-P53 at serine 15 and 37 upon ATRA treatment.Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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ATRA was shown to suppress tumor growth by regulating
a known tumor suppressor P53 [36-38]. We have previ-
ously shown that Chmp1A over-expression induced an
accumulation of P53 and phospho-P53 (at serine 15 and
37 position) in PanC-1 cells [22]. Thus we investigated
whether ATRA controls P53 and phospho-P53 protein
expression in ATRA responsive cell lines. Western blot
analyses (shown in Figures 2C and 3C) demonstrated that
ATRA increased the protein expression of P53 and phos-
pho-P53 in Capan-2 and PanC-1 cells. Although Capan-2
cells did not show growth inhibition on Day 1, it showed
the most significant ratio of increase in phospho-P53 (at
serine 15 and 37) one day after ATRA treatment (Figure
2C). PanC-1 cells also showed an increase in phospho-
P53 (at serine 15 and 37) one day after ATRA treatment
(Figure 3C). The ratio of increase in phospho-P53 dimin-
ished drastically in Capan-2 cells and gradually in PanC-1
cells from Day 2 on, exhibiting robust expression of phos-
pho-P53 (at serine 15) on Day 2 and 3 in Capan-2, and on
Day 2 in PanC-1 cells, respectively. As for total P53 expres-
sion, Capan-2 cells showed a strong expression as well as
an increase on Day 1. From Day 2 on, P53 expression
reduced noticeably, still maintaining an increase in its
expression upon ATRA treatment (Figure 2C). PanC-1
cells also showed an increase of P53 expression up to Day
3 upon ATRA treatment (Figure 3C).
Chmp1A and P53 expression was not changed in ATRA 
non-responsive cells
To further determine whether the increase of Chmp1A
protein is essential for the growth inhibition of ATRA we
treated CRL-2151 cells with ATRA. This cell line was pre-
viously shown to be resistant to ATRA-mediated growth
inhibition [39]. Consistent with previous reports ATRA
did not inhibit growth of CRL-2151 cells (Figure 4A). P-
values showed there was no significant differences
between DMSO and ATRA treated cells (P-values; 0.18,
0.196, 0.195, and 0.23 on day 1, 2, 3, and 4, respectively
in Figure 4A). In ATRA-responsive cells Chmp1A protein
expression was increased upon ATRA treatment (Figures
2B and 3B). However, as shown in Figure 4B, the Chmp1A
protein level was not changed in CRL-2151 cells, up to
four days after ATRA treatment. In addition, as shown in
Figure 4B, the expression level of total P53 and phospho-
P53 (at serine 15) remained similar in ATRA treated cells
compared to control cells, indicating the parallel relation
between growth inhibition and accumulation of
Chmp1A, P53, and phospho-P53 protein.
The growth inhibition of PanC-1 cells by ATRA was accompanied by an increase of Chmp1A, CRBP-1, P53 and phospho-P53  protein expression Figure 3
The growth inhibition of PanC-1 cells by ATRA was accompanied by an increase of Chmp1A, CRBP-1, P53 and 
phospho-P53 protein expression. (A) PanC-1 cells were counted and equal numbers of cells were seeded in 10 cm tissue 
culture dishes. Next day, cells were treated with DMSO or ATRA. The following 4 days, cells were counted and plotted for 
the graph. Dashed line with square represents DMSO treated and straight line with circle represents ATRA treated. P value 
indicates a significant growth inhibition by ATRA treatment. (B, C) The cells were processed for Western blot analysis after 
lysis. Notice the increase of Chmp1A and CRBP-1, P53 and phospho-P53 upon ATRA treatment.Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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Chmp1A over-expression inhibited growth of CRL-2151 
cells that accompanied by an increase in P53 and 
phospho-P53
Above results demonstrated that CRL-2151 cells neither
showed growth inhibition nor any increase in the expres-
sion of Chmp1A, P53 or phospho-P53 when they were
treated with ATRA. Thus we over-expressed Chmp1A and
tested whether it had any effect on the growth of CRL-
2151 cells. As shown in Figure 4D, Chmp1A protein level
was increased upon Chmp1A over-expression 1 and 2
days after transfection (shown here is 1 day after transfec-
tion). We did not observe an increase of Chmp1A protein
3 days after transfection (data not shown). In addition,
CRL-2151 cells demonstrated growth inhibition when
Chmp1A was over-expressed (Figure 2C). The growth
inhibition induced by transient over-expression of
Chmp1A was temporary, limited to one day but main-
tained the following days. Since we have shown that
Chmp1A over-expression induces growth inhibition of
PanC-1 cells by regulating P53 signaling [22], we investi-
gated the expression of P53 and phospho-P53 in Chmp1A
over-expressing CRL-2151 cells. As shown in Figure 4D,
the protein expression of P53, and phospho-P53 (at ser-
ine 15 and 37) was increased a day after transient over-
expression of Chmp1A. Densitometric analysis (Figure
4E) demonstrates significant changes in protein expres-
sion, showing 2.5, 3.3, 4.3 and 1.8 fold increase of
Chmp1A, phopsho-P53 (serine 15), phopsho-P53 (serine
37), and total P53 respectively.
Chmp1A is required for ATRA mediated growth inhibition
Next we investigated whether Chmp1A is required for the
growth inhibition of ATRA. We generated stable clones
that express shRNA to knockdown Chmp1A in PanC-1
cells. Before we used the stable knockdown clones for
growth assays, we tested the knockdown efficiency by
ATRA resistant CRL-2151 cells did not show changes in Chmp1A, P53 or phospho-P53 upon ATRA treatment but showed  growth inhibition and an increase in the expression of these proteins upon Chmp1A over-expression Figure 4
ATRA resistant CRL-2151 cells did not show changes in Chmp1A, P53 or phospho-P53 upon ATRA treatment 
but showed growth inhibition and an increase in the expression of these proteins upon Chmp1A over-expres-
sion. (A) CRL-2151 cells were counted and equal numbers of cells were seeded in 10 cm tissue culture dishes. Next day cells 
were treated with control DMSO or ATRA. The following 4 days, cells were counted and plotted for the graph. Black line with 
circle represents DMSO treated and gray line with square represents ATRA treated. Notice that there is no significant change 
in growth between DMSO and ATRA treated cells. (B) The cells were processed for Western blot analysis following lysis. 
Chmp1A, P53 and phospho-P53 protein expression showed no difference with DMSO or ATRA treated cells. Gapdh indicates 
the equal loading of samples. (C-E) Growth was inhibited a day after transfection with Chmp1A compared to control (C). The 
expression of Chmp1A, P53 and phospho-P53 (at serine 15 and 37) was increased a day after transfection with Chmp1A com-
pare with control (D). Densitometric analysis was performed and the change of protein level was determined by setting con-
trol as "1" after corrected for Gapdh (E).Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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Western blot analysis. Knockdown stable clone 1 and 2
(KD1 and KD2) showed a significant decrease of Chmp1A
protein (Figure 5A), 77% and 85%, respectively, com-
pared to a non-silencing shRNA expressing control clone.
Since stable clone 2 showed greater knockdown efficiency
we used these clone of cells for the following growth and
Western blot analyses.
We treated cells stably expressing either control or
Chmp1A shRNA with ATRA (or DMSO as control) to test
whether Chmp1A was required for growth inhibition of
ATRA signaling. Similar to non-treated cells, the non-
silencing shRNA-expressing cells exhibited significant
growth inhibition upon ATRA treatment (black solid
line), compared with DMSO treatment (black dashed
line, P < 0.05) (Figure 5C). On the other hand, the cells
that stably express Chmp1A shRNA promoted cell growth
in the presence of ATRA or DMSO. The growth promotion
by Chmp1A knockdown was obvious in the DMSO
treated cells (gray dashed line) as well as in the ATRA
treated cells (gray solid line) compared with control.
Importantly, ATRA treated PanC-1 cells that express
Chmp1A shRNA revealed the same growth pattern as
DMSO treated cells demonstrating that ATRA signaling is
not translated to growth inhibition in the absence of
Chmp1A (P > 0.05). In addition, the growth was pro-
moted in both ATRA and vehicle treated PanC-1 cells that
express Chmp1A shRNA compared to the cells that
express non-silencing shRNA. Our data indicates that
Chmp1A knockdown mediates growth promotion, and
Chmp1A knockdown abolished ATRA mediated growth inhibition and the increase of protein levels of Chmp1A, CRBP, P53  and phospho-P53 Figure 5
Chmp1A knockdown abolished ATRA mediated growth inhibition and the increase of protein levels of 
Chmp1A, CRBP, P53 and phospho-P53. (A) Chmp1A shRNA was cloned into shRNA RNAintro™ pSM2 retroviral vec-
tor to generate stable PanC-1 clones expressing Chmp1A shRNA. Western blot analysis demonstrated the knockdown effi-
ciency of two colonies (KD1 and KD2). Non-silencing shRNA was used as control. (B) Chmp1A expression was reduced in 
Chmp1A silenced PanC-1 cells more than 50% on Day 1 and 40% on Day 2 regardless of ATRA treatment, compared with 
non-silencing shRNA expressing cells that were treated with vehicle DMSO. ATRA treatment increased Chmp1A expression 
slightly. (C) Silencing of Chmp1A induced growth promotion in the presence or absence of ATRA, compared with control cells 
that were treated with either DMSO or ATRA. ATRA did not have an effect on growth upon stable expression of Chmp1A 
shRNA compared to control shRNA. (D) Control shRNA expressing cells showed an increase in P53 and phospho-P53 at ser-
ine 15 and 37 without exhibiting an increase in CRBP-1. However, Chmp1A shRNA expressing cells exhibited a decline in 
CRBP-1 and phospho-P53 expression at serine 15 and 37 when compared with control shRNA expressing cells that were 
treated with DMSO. ATRA increased P53 expression when Chmp1A was silenced, however, Chmp1A depletion did not 
decrease P53 expression. D: DMSO, R: ATRAMolecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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that Chmp1A is indispensable for the growth inhibition
of ATRA signaling.
The knockdown of Chmp1A diminished the ATRA 
mediated increase in protein expression level of Chmp1A, 
CRBP-1, and phospho-P53
We have shown that Chmp1A expression is increased
upon ATRA treatment in PanC-1 cells (Figure 3B). Thus
we tested whether Chmp1A expression was changed upon
ATRA treatment in Chmp1A depleted PanC-1 cells. In the
control shRNA-expressing cells, Chmp1A expression was
increased slightly compared with control upon ATRA
treatment (1.3 and 1.6 fold increase on Day 1 and 2,
respectively) (Figure 5B). However, in the Chmp1A
shRNA-expressing cells, Chmp1A expression was
decreased on both Day 1 and 2 compared to that of con-
trol, from 1 to 0.5 (DMSO) and 0.11 (RA) and from 1 to
0.6 (DMSO) and 0.6 (RA) on Day 1 and 2 each, demon-
strating the knockdown efficiency of Chmp1A. In addi-
tion, Chmp1A protein level was not increased upon ATRA
treatment in Chmp1A depleted cells compared to control,
confirming the requirement of Chmp1A in ATRA medi-
ated growth inhibition.
Next we tested whether Chmp1A knockdown affected the
protein expression of CRBP-1, total P53 and phospho-
P53 at serine 15 and 37. The changes in CRBP-1 protein
made by Chmp1A knockdown followed by ATRA treat-
ment were somewhat complicated. CRBP-1 protein was
increased upon ATRA treatment on Day 1 (data not
shown) in control cells, which was decreased a little on
Day 2. However, its expression went down 50% when
Chmp1A was silenced, which increased slightly upon
ATRA treatment on Day 2 (Figure 5D). As for P53 and
phospho-P53, we have noticed significant changes 2 days
after ATRA treatment only. In control shRNA-expressing
cells, ATRA treatment elevated P53 and phospho-P53
expression that was similar to what we have observed
from non-treated PanC-1 cells (compare Figure 5D to Fig-
ure 3C, Day 1 or Day 2). In Chmp1A depleted cells, the
knockdown of Chmp1A did not abolish the ATRA medi-
ated increase in total P53 expression. However, phospho-
P53 expression was decreased upon DMSO or ATRA treat-
ment compared with DMSO treated control shRNA
expressing cells, from 1 to 0.07 (DMSO) and 0.28 (RA) at
serine 15, and from 1 to 0.6 (DMSO) and 0.5 (RA) at ser-
ine 37 each.
Nuclear expression of Chmp1A is important for ATRA 
mediated growth inhibition
ATRA is known to exert its effect via interacting with its
nuclear receptors [3,40]. It is possible that ATRA regulates
cellular growth by enhancing the nuclear localization of
Chmp1A since Chmp1A is distributed in the nucleus [19].
We tested this hypothesis by investigating the sub-cellular
distribution of Chmp1A in the presence of vehicle DMSO
or ATRA. Confocal microscopic analysis demonstrated
that Chmp1A expression was ubiquitous with robust
staining in the nucleus in ATRA responsive PanC-1 cells.
When cells were treated with ATRA, Chmp1A was
increased especially in the nucleus compared to control
(Figures 6. Ab and d compare with 6. Aa and 6. Ac). In
ATRA non-responsive cells, Chmp1A expression was also
ubiquitous initially and up to day 2, with or without
ATRA treatment (Figures 6. Ba and 6. Bb). However, by
day three, Chmp1A was translocated into the plasma
membrane and remained at the membrane in both ATRA
and DMSO treated cells (Figures 6. Bc and 6. Bd).
Discussion
In this study we provide a new insight into the function
and mechanism of the Chmp1A, a member of the ESCRT-
III family. As shown in our model in the conclusion,
Chmp1A positively regulates CRBP-1 expression. In turn,
CRBP-1 augments the availability of ATRA via controlling
the storage and metabolism of retinol A [7,41,42]. ATRA
then increases the protein level of Chmp1A, which subse-
quently causes an accumulation of P53 and phopspho-
P53. This model proposes a positive amplification of
ATRA signaling resulting in the inhibition of tumor cell
proliferation mediated in part by Chmp1A.
CRBP-I binds retinol and is thought to carry this retinoid
to various enzymes for its metabolism to retinoic acid [7].
The expression of CRBP-1 is reduced in various tumors
including breast [8], prostate [42], ovarian [43], and
endometrial carcinomas [44]. The decrease of cytoplasmic
immunoreactivity of CRBP-1 is associated with the
increase of tumor grade in endometrioid carcinomas [44].
In our study, we have shown that Chmp1A positively reg-
ulated the expression of CRBP-1 at the mRNA level in HEK
293T (Figure 1A). At the protein level, however, CRBP-1
did not show significant changes either by Chmp1A over-
expression (Figure 1B) or by ATRA treatment (Figures 2B,
3B and 5D) although it showed a major decrease by
Chmp1A knockdown (Figure 5D). A similar observation
was made previously. Treating Sertoli cells with either
stimulants or inhibitors of CRBP-1 resulted in significant
changes in CRBP-1 mRNA levels. However, very little
changes were observed at the protein level [45], indicating
that the regulation of CRBP-1 protein is not directly corre-
lated with that of CRBP-1 mRNA. As for a mechanism, we
found SPFH domain containing proteins as Chmp1A
binding partners (Belogortseva and Park, unpublished).
CRBP-1 protein localizes to lipid rafts, specialized mem-
brane domains, where retinol is stored [7]. SPFH domain-
containing proteins are also found in the lipid rafts of var-
ious membranes including plasma membrane and endo-
somes [46]. Thus it is possible that Chmp1A, by
interacting with SPFH-domain containing proteins atMolecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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Chmp1A was translocated to the nucleus in ATRA responsive cells but to the membrane in ATRA resistant cells upon ATRA  treatment (A and B), and Model (C) Figure 6
Chmp1A was translocated to the nucleus in ATRA responsive cells but to the membrane in ATRA resistant 
cells upon ATRA treatment (A and B), and Model (C). (A) In the presence of DMSO, Chmp1A expression was mod-
estly detected both in the nucleus and cytoplasm in PanC-1 cells (a, c). However, Chmp1A protein expression became robust 
in the presence of ATRA, especially in the nucleus (n in c, d). (a, b) and (c, d) is one and two days after vehicle or ATRA treat-
ment, respectively. (B) Chmp1A was initially distributed ubiquitously in CRL-2151 cells in the presence of DMSO or ATRA (a, 
b). From Day 3 on, however, Chmp1A protein was mainly detected and remained at the membrane (arrows in c, d) in both 
DMSO and ATRA treated cells. (a, b) is for Day 2 and (c, d) is for Day 3 after DMSO and ATRA treatment, respectively. (C) 
Model: Chmp1A mediates growth inhibition of ATRA signaling. Chmp1A positively regulates the expression of CRBP-1. In 
turn, CRBP-1 controls the activity of ATRA via regulating the storage and metabolism of retinol A. ATRA treatment produces 
an increase in the expression level of Chmp1A in the nucleus, which leads to the accumulation of total and 'active' P53 resulting 
in a decrease in cell proliferation.Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
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lipid rafts of various membranes, could have an effect on
CRBP-1 and retinol storage.
We examined the involvement of Chmp1A in ATRA sign-
aling by determining the effect of ATRA on Chmp1A
expression in pancreatic tumor cell lines. We chose two
ATRA responsive cell lines and one ATRA non-responsive
cell line for our experiments. Capan-2 and PanC-1 cells
are well- and poorly-differentiated human pancreatic duc-
tal tumor cells, respectively, whose growth was inhibited
by ATRA treatment. Capan-2 cells have longer doubling
time compare to PanC-1 cells and the longer doubling
time was reflected in ATRA-mediated growth inhibition
(compare Figure 2A to 3A). CRL-2151 is a mouse pancre-
atic acinar tumor cell line that did not show growth inhi-
bition upon ATRA treatment. Our results on ATRA-
mediated growth inhibition of pancreatic tumor cells are
consistent with the already published reports
[30,33,39,47]. However, the increase of Chmp1A upon
ATRA treatment in two ATRA responsive cell lines is a
novel finding.
Our observation that ATRA increased P53 and phospho-
P53 expression also agrees with several reports demon-
strating that ATRA inhibits tumor growth by regulating
P53 expression and activity [37,48]. This data is also con-
sistent with our previous report [22], demonstrating that
Chmp1A functions as a tumor suppressor in pancreatic
tumor in vitro and in vivo in part by regulating P53. The
activation and stabilization of P53 are thought to be
mediated by post-translational modification of protein,
with phosphorylation being the major event [49].
Although the exact function of specific phosphorylation
events remains controversial, evidence indicates that they
contribute to both stabilization and activation of P53.
Phosphorylation of P53 at ser15 and apparently at 37 is
due to activation of ATM [50]. Recent study indicates that
ATRA activates ATM, but the mechanism underlying ATRA
mediated activation of ATM remains unclear. It was
shown previously that Chmp1A has a strong effect on
chromatin structure [19]. Thus, the potential explanation
in the light of our data may be that ATRA mediated
Chmp1A expression can lead to changes of chromatin
structure and subsequent ATM activation.
We tested whether Chmp1A is required for ATRA-induced
growth inhibition by knockdown Chmp1A expression
using shRNA. Non-silencing shRNA expressing PanC-1
cells exhibited a similar growth inhibition to non-treated
PanC-1 cells when treated with ATRA compared to control
(Figure 5C, black lines, compare with Figure 3A). How-
ever, Chmp1A shRNA expressing PanC-1 cells that greatly
reduced Chmp1A protein level did not show any differ-
ence in growth with ATRA treatment as shown in Figure
5C. ATRA treated cells showed the same growth pattern as
control DMSO treated cells. Moreover, Chmp1A knock-
down resulted in growth promotion of pancreatic ductal
tumor cells in the presence or absence of ATRA relative to
cells expressing control shRNA. These results suggest that
Chmp1A is essential for growth inhibition by ATRA and
agree with our previous data demonstrating that Chmp1A
inhibits tumor growth independent of ATRA in human
pancreatic cancer cells [22].
Previously, we have shown that over-expression of
Chmp1A leads to the accumulation of P53 and phospho-
P53 at serine 15 and 37 [22]. The same stable clones were
used to test Chmp1A and CRBP-1 expression by Chmp1A
over-expression (Figure 1B). Based on these experiments,
we speculated that P53 and phospho-P53 expression
would be decreased when Chmp1A expression is
depleted. When Chmp1A is depleted, phospho-P53
expression did go down at both serine 15 and 37 posi-
tions, compared with control (Figure 5D). As for total
P53, silencing of Chmp1A did not decrease its expression
on Day 2. Since it takes considerable time for shRNA to
exert its effect fully, we speculate that P53 expression is
still high in Chmp1A shRNA-expressing cells. However, it
is possible that the level of phospho-P53, not total P53,
might be important in Chmp1A-mediated growth regula-
tion. Interestingly though, ATRA induced an increase of
P53 and phospho-P53 in both control and Chmp1A
shRNA expressing cells. As shown in Figure 5A, Chmp1A
silenced cells still express small amounts of Chmp1A that
could respond to ATRA, which relates to the increase of
P53 and phospho-P53 expression in Chmp1A shRNA-
expressing cells. We also used Chmp1A small interfering
RNA (siRNA) to silence Chmp1A transiently, and
obtained similar results in growth and protein expression
in Chmp1A (data not shown).
The model (Figure 6C) is further supported by our exper-
iments with ATRA resistant cells. Since human pancreatic
acinar tumor cell lines are not available, we used mouse
pancreatic acinar tumor cells for this assay. We hypothe-
sized that ATRA non-responsive cells should not show any
difference in Chmp1A protein levels. Our data indeed
demonstrated that the expression of Chmp1A did not
change upon ATRA treatment. In addition, we did not
observe any change in the protein expression of P53 or
phospho-P53. We further investigated whether transient
over-expression of Chmp1A could make ATRA-resistant
cells respond to signals for growth inhibition. CRL-2151
cells showed growth inhibition followed by an increase in
P53 and phospho-P53 expression. These results strongly
demonstrate that Chmp1A is essential for ATRA-mediated
growth inhibition, and that Chmp1A also functions inde-
pendently of ATRA even though it's employing the same
downstream target, P53, for growth inhibitory effects.
ATRA-independent functions of Chmp1A in human pan-Molecular Cancer 2009, 8:7 http://www.molecular-cancer.com/content/8/1/7
Page 12 of 13
(page number not for citation purposes)
creatic ductal tumor and embryonic kidney (PanC-1 and
HEK 293T respectively) were described in our previous
paper in detail [22].
We also investigated whether ATRA had any effect on the
nuclear localization of Chmp1A. In the absence of ATRA,
Chmp1A was expressed ubiquitously in the cytoplasm
and the nucleus (Figure 6) in both ATRA-responsive and
non-responsive cells. However, Chmp1A protein had
stronger nuclear localization upon ATRA treatment in
ATRA responsive cells. In the ATRA non-responsive cells,
addition of ATRA resulted in translocation of Chmp1A to
the plasma membrane. These results indicate that nuclear
localization of Chmp1A might be important for its ability
to regulate cell proliferation through ATRA-signaling
activity. Since ATRA responsive PanC-1 cells also showed
significant increase in cytoplasmic expression of Chmp1A
upon ATRA treatment (Figures 6Ab and 6Ad), we can't
rule out the involvement of cytoplasmic Chmp1A in
ATRA mediated growth inhibition.
Conclusion
In this study, we provide novel mechanisms by which cer-
tain tumors are more sensitized to ATRA treatment than
others. Our study indicates that not only the level of, but
also the nuclear localization of Chmp1A is important in
the mediation of growth inhibition of ATRA signaling,
partly through the positive regulation of CRBP-1 (Figure
6C, Model). By developing methods to mimic Chmp1A
functions, our data could lead to development of thera-
peutic reagents targeted to treat both ATRA sensitive and
resistant tumors.
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